Journavx (suzetrigine)
Active
Vertex Pharmaceuticals
Overview
A first-in-class oral, non-opioid pain medicine (VX-548) that selectively inhibits the NaV1.8 sodium channel to block pain signals in the peripheral nervous system before they reach the brain — the first new class of pain drug in over 20 years.
FDA-approved January 30, 2025 for moderate-to-severe acute pain and launching commercially, with label-expansion studies into chronic pain (including diabetic peripheral neuropathy) under way.